Showing results (491-500 of 577) with videos related to

Sort By:
Pageof 58
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
The New England Journal of Medicine|September 13, 2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerJean-Yves Douillard, Kelly S Oliner, Salvatore Siena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAActSheela Rao, Francesco Sclafani, Cathy Eng, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 25, 2015
International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancerKyoichi Takaori, Claudio Bassi, Andrew Biankin, et al.
Oncogene|June 1, 2019
Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSteve Wagner, Georgios Vlachogiannis, Alexis De Haven Brandon, et al.
Oncogene|October 25, 2018
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSteve Wagner, Georgios Vlachogiannis, Alexis De Haven Brandon, et al.
Nature Structural & Molecular Biology|April 17, 2007
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaDavid Cunningham, Dennis E Danley, Kieran F Geoghegan, et al.
The Lancet. Oncology|November 22, 2012
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, et al.
Pageof 58